- Predictive tools will seek to reduce leading cause of
failure rates in clinical trials of oncology drugs.
- Integrated AI and microscopy expected to lead to better
understanding of tumor structures and treatment
strategies.
- New technology will work to capture and analyze the highly
heterogeneous tumor microenvironment.
WASHINGTON, July 11,
2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR),
a global science and technology innovator, today launched a
research collaboration with Stanford
University's Department of Bioengineering intended to shape
the future of cancer drug screening through "smart microscopy."
Combining spatial biology with artificial intelligence (AI), the
research team at the Danaher Beacon for Spatialomics aims to help
de-risk cancer drug development.
Tumors are highly variable, not just from tumor to tumor but
within each tumor itself. This variation in the "microenvironment"
leads to unpredictable clinical outcomes, including high failure
rates during clinical trials. The collaboration aims to leverage
the latest findings in spatial biology coupled with cutting-edge AI
to make it possible to screen more complex cellular systems.
Chandra Ramanathan, VP and
Head of External Innovation of Danaher's DH Life Sciences LLC
subsidiary, said: "Many oncology drug trials fail because we
cannot yet capture and analyze the nuances of the tumor
microenvironment and how key proteins spatially interact with each
other. Addressing this challenge will require collecting data at
scale and designing new ways to analyze it. We are delighted to
commit Danaher's expertise to seek to develop AI-driven phenotyping
that could improve drug screening and bring more effective and
safer drugs to cancer patients."
Emma Lundberg, Ph.D.,
Associate Professor of Bioengineering and Pathology at Stanford University, said: "We're at the
brink of a new era when it comes to spatial biology and structural
cell modeling. This research collaboration will seek to apply the
latest microscopy and AI tools at the scale needed to understand
treatment responses based on differences in protein expression that
change across regions of the tumor."
The collaboration is a partnership between Leica Microsystems, a
Danaher subsidiary, and Lundberg, a researcher and leader in the
field of spatial proteomics and cell biology known for her
involvement in the Human Protein Atlas project. The outcome could
be an analysis engine that can detect spatial, proteomic, and
metabolic changes in the tumor microenvironment and more accurately
predict how tumors will respond to potential therapies.
The collaboration is the latest addition to the Danaher Beacons
program, which funds product-driven scientific research with
globally recognized academic investigators.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics
innovator, committed to accelerating the power of science and
technology to improve human health. Our businesses partner closely
with customers to solve many of the most important health
challenges impacting patients around the world. Danaher's advanced
science and technology - and proven ability to innovate - help
enable faster, more accurate diagnoses and help reduce the time and
cost needed to sustainably discover, develop and deliver
life-changing therapies. Focused on scientific excellence,
innovation and continuous improvement, our approximately 63,000
associates worldwide help ensure that Danaher is improving quality
of life for billions of people today, while setting the foundation
for a healthier, more sustainable tomorrow. Explore more at
www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including any statements regarding events or developments that
Danaher believes or anticipates will or may occur in the future are
"forward-looking" statements within the meaning of the federal
securities laws. These factors include, among other things:
unanticipated, further declines in demand for our COVID-19 related
products, the impact of global health crises, the impact of our
debt obligations on our operations and liquidity, deterioration of
or instability in the global economy, the markets we serve and the
financial markets, uncertainties with respect to the development,
deployment, and use of artificial intelligence in our business and
products, uncertainties relating to national laws or policies,
including laws or policies to protect or promote domestic interests
and/or address foreign competition, contractions or growth rates
and cyclicality of markets we serve, competition, our ability to
develop and successfully market new products and technologies and
expand into new markets, the potential for improper conduct by our
employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to
off-label marketing and other regulations relating to medical
devices and the health care industry), the results of our clinical
trials and perceptions thereof, our ability to effectively address
cost reductions and other changes in the health care industry, our
ability to successfully identify and consummate appropriate
acquisitions and strategic investments, our ability to integrate
the businesses we acquire and achieve the anticipated growth,
synergies and other benefits of such acquisitions, contingent
liabilities and other risks relating to acquisitions, investments,
strategic relationships and divestitures (including tax-related and
other contingent liabilities relating to past and future IPOs,
split-offs or spin-offs), security breaches or other disruptions of
our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to
grow, risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the
United States government with respect to our production
capacity in times of national emergency or with respect to
intellectual property/production capacity developed using
government funding, risks relating to product, service or software
defects, product liability and recalls, risks relating to our
manufacturing operations and fluctuations in the cost and
availability of the supplies we use (including commodities) and
labor we need for our operations, our relationships with and the
performance of our channel partners, uncertainties relating to
collaboration arrangements with third-parties, the impact of
deregulation on demand for our products and services, the impact of
climate change, legal or regulatory measures to address climate
change and our ability to address stakeholder expectations relating
to climate change, labor matters and our ability to recruit, retain
and motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal,
compliance, social and business factors (including the impact of
military conflicts), disruptions relating to man-made and natural
disasters, inflation and the impact of our By-law exclusive forum
provisions. Additional information regarding the factors that
may cause actual results to differ materially from these
forward-looking statements is available in our SEC filings,
including our 2023 Annual Report on Form 10-K and Quarterly Report
on Form 10-Q for the first quarter of 2024. These
forward-looking statements speak only as of the date of this
release and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise.
View original
content:https://www.prnewswire.com/news-releases/danaher-launches-beacon-research-collaboration-with-stanford-university-aiming-to-build-next-generation-of-smart-microscopes-for-cancer-drug-screening-302194405.html
SOURCE Danaher Corporation
